FATE
Fate Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$262.26M
P/E Ratio
—
EPS
$-1.09
Beta
2.14
52W High
$2.46
52W Low
$0.91
50-Day MA
$1.50
200-Day MA
$1.25
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $6.32M |
| Gross Profit (TTM) | $-81.15M |
| EBITDA | $-125.84M |
| Operating Margin | -2540.00% |
| Return on Equity | -55.50% |
| Return on Assets | -25.30% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $1.55 |
| Price-to-Book | 1.45 |
| Price-to-Sales (TTM) | 41.52 |
| EV/Revenue | 25.82 |
| EV/EBITDA | -2.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -20.30% |
| Shares Outstanding | $116.56M |
| Float | $102.47M |
| % Insiders | 1.21% |
| % Institutions | 80.13% |
Historical Volatility
HV 10-Day
132.52%
HV 20-Day
161.72%
HV 30-Day
135.25%
HV 60-Day
108.35%
HV Rank
98.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($5.41 target)
1
Strong Buy4
Buy6
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026